-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $24

Benzinga·11/04/2026 14:22:05
Listen to the news
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $23 to $24.